Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 2/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460315 | 0.93 | KDR (0.77) | KDRCDK8BRAFRAF1 | |
| SCHEMBL5432163 | 0.91 | KDR (0.56) | KDRNTRK1BRAFRAF1 | |
| SCHEMBL5335414 | 0.90 | KDR (0.58) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5417893 | 0.89 | KDR (0.68) | KDRBRAFRAF1 | |
| SCHEMBL5436585 | 0.89 | KDR (0.70) | KDRBRAFRAF1RET | |
| SCHEMBL27847250 | 0.89 | KDR (0.87) | KDRNTRK1CDK8RAF1RET | |
| SCHEMBL5349430 | 0.88 | NTRK1 (0.67) | KDRNTRK1BRAFRET | |
| SCHEMBL5448287 | 0.88 | KDR (0.56) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5338893 | 0.88 | KDR (0.56) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5421657 | 0.87 | KDR (0.57) | KDRCDK8BRAFRAF1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102406647-A | New application of aryl urea derivative in preparing medicine for treating renal tumor | UNIV PEKING FOUNDER GROUP CO | 2012-04-11 | — | — | CN | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 555/4885NTRK1 578/4885CDK8 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.